Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time

Duration of initial disease response remains a strong prognostic factor in multiple myeloma (MM) particularly for upfront autologous hematopoietic cell transplant (AHCT) recipients. We hypothesized that new drug classes and combinations employed prior to AHCT as well as after post-AHCT relapse may h...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia 2018-04, Vol.32 (4), p.986-995
Main Authors: Kumar, S K, Dispenzieri, A, Fraser, R, Mingwei, F, Akpek, G, Cornell, R, Kharfan-Dabaja, M, Freytes, C, Hashmi, S, Hildebrandt, G, Holmberg, L, Kyle, R, Lazarus, H, Lee, C, Mikhael, J, Nishihori, T, Tay, J, Usmani, S, Vesole, D, Vij, R, Wirk, B, Krishnan, A, Gasparetto, C, Mark, T, Nieto, Y, Hari, P, D'Souza, A
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Autografts
Cancer recurrence
Care and treatment
Female
Hematopoietic stem cell transplantation
Hematopoietic Stem Cell Transplantation - methods
Humans
Immunoglobulin A
Immunoglobulin A - metabolism
Induction therapy
Maintenance
Male
Middle Aged
Multiple myeloma
Multiple Myeloma - metabolism
Multiple Myeloma - pathology
Neoplasm Recurrence, Local - metabolism
Neoplasm Recurrence, Local - pathology
Patient outcomes
Patients
Prognosis
Recurrence
Risk factors
Risk reduction
Stem cell transplantation
Transplantation
Transplantation, Autologous - methods
Transplants & implants
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Duration of initial disease response remains a strong prognostic factor in multiple myeloma (MM) particularly for upfront autologous hematopoietic cell transplant (AHCT) recipients. We hypothesized that new drug classes and combinations employed prior to AHCT as well as after post-AHCT relapse may have changed the natural history of MM in this population. We analyzed the Center for International Blood and Marrow Transplant Research database to track overall survival (OS) of MM patients receiving single AHCT within 12 months after diagnosis (N=3256) and relapsing early post-AHCT (
ISSN:0887-6924
1476-5551
DOI:10.1038/leu.2017.331